Neonatal sepsis is a leading cause of global mortality in children under five years old. According to the Global Sepsis Alliance, infections leading to sepsis are responsible for about one fifth of the world's annual 2.7 million neonatal deaths, especially in South Asia and sub-Saharan Africa.
Neonatal sepsis is a leading cause of global mortality in children under five years old. According to the Global Sepsis Alliance, infections leading to sepsis are responsible for about one fifth of the world’s annual 2.7 million neonatal deaths, especially in South Asia and sub-Saharan Africa.
Prompt diagnosis and treatment of neonatal early onset sepsis is crucial to prevent severe morbidity and mortality. However, rapid and accurate diagnosis is often difficult in routine clinical practice because clinical manifestations of this condition can overlap with those of non-infectious conditions.
Here, the laboratory parameter B-R-A-H-M-S PCT can provide valuable information for the detection of neonatal sepsis from the first day of life.
Procalcitonin (PCT) is the prohormone of the hormone calcitonin, and helps to differentiate bacterial from viral infections or other causes of systemic inflammation. Immediately after birth, newborns show a physiological elevation of PCT. Therefore, using PCT in neonates during their first 48-72 hours of life, age-specific PCT reference values apply: in healthy neonates, plasma PCT concentrations increase gradually after birth, reaching peak values at about 24 hours of age, and then decrease to normal values of less than 0.5_g/L by 48-72 hours of age.
Antibiotic treatment is started early in newborns who are at risk from infection in order to prevent a possible bacterial infection before it sets in. As a consequence, up to 7% of all newborn babies receive antibiotics within their first three days of life. However, a considerable number of these babies are exposed to antibiotics unnecessarily, as only 0.1% of them have such an infection.
This overuse of powerful antibiotics can have a damaging effect on an infant’s developing immune system. Disruption of a baby’s microbiome has been linked to several chronic conditions, including allergies, obesity, diabetes and inflammatory bowel disease.
Recently, The Lancet published the results of a new multicenter, randomised controlled trial (NeoPInS) where 1,710 patients had been enrolled in 18 hospitals in the Netherlands, Switzerland, Canada and the Czech Republic in order to evaluate a B-R-A-H-M-S PCT-based clinical algorithm to guide antibiotic therapy decisions in term and near-term neonates with low likelihood of bacterial infection. The study demonstrated that PCT-guided decision-making was superior to the standard care approach, enabling a 15-19% reduction of antibiotic-therapy duration in these newborns.
It also suggests that higher adherence to the PCT algorithm could further increase this effect. As additional analysis revealed, the adherent group had a 25-hour shorter median duration compared with the non-adherent group, resulting in a 34% shorter AB duration compared with standard of care.
Thus, PCT can be an important tool, not only for the early detection of sepsis in neonates, but also to guide antibiotic treatment duration and reduce antibiotic exposure of neonates.
B-R-A-H-M-S PCT can provide valuable information for the detection of neonatal sepsis from the first day of life.
Thermo Fisher Scientific
168 Third Avenue Waltham, MA USA 02451
Tel: 781-622-1000; 800-678-5599
United States of America
In the hospital environment, where making the correct decision quickly can have exponential benefits for clinical outcomes, speed and availability are of the essence. Thermo Fisher Scientific has therefore developed the first quantitative whole blood point-of-care procalcitonin test.Download White Paper
In emergency departments, unforeseeable situations are routine. Ever-more rapid and reliable results are vital, and can have exponential benefits with regard to clinical outcomes and patient management. Thermo Fisher Scientific has developed the first quantitative whole-blood point-of-care procalcitonin (PCT) test to help medical staff to make informed decisions.Download White Paper
Antibiotics can save lives, but their increasingly unwarranted use in healthcare is causing the growth of antimicrobial resistance. Thermo Fisher Scientific’s B·R·A·H·M·S procalcitonin can help to reduce unnecessary antibiotic prescriptions.Download White Paper
Overuse of antibiotics is a global problem, but the biomarker procalcitonin (PCT), such as the B·R·A·H·M·S PCT assay from Thermo Fisher Scientific, can help guide antibiotic stewardship and reduce resistance to the effects of these drugs. Basel University Hospital’s Dr Philipp Schuetz from the department of internal medicine discusses the importance of the biomarker.Download White Paper
Neonatal infections remain a challenge for today’s physicians, as early signs and symptoms are often protean and non-specific. B·R·A·H·M·S PCT, developed by Thermo Fisher Scientific, can help to detect neonatal sepsis and assist in safe antibiotic guidance.Download White Paper
Accurate antimicrobial susceptibility testing affects not only sepsis patients, but also those around them should the infection have a chance to spread. Professor Rafael Canton of the Ramón and Cajal University Hospital explains why the continuous development of testing products – such as those created by Thermo Fisher Scientific – is essential.Download White Paper
CARLSBAD, Calif. -- Thermo Fisher Scientific Inc., the world leader in serving science, today announced its collaboration with the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) Initiative, Helix, and Rosalind aimed at developing a new genotyping method for SARS-CoV-2 that could speed up the identification of variants as they emerge.
The PCR assay panel tests for five respiratory viruses in under three hours
Assay helps detect drug resistant strains of HIV-1
Updated qPCR system now includes integrated software to support growing test menus for clinical laboratories and assay developers
CARLSBAD, Calif.--(BUSINESS WIRE)-- Thermo Fisher Scientific, the world leader in serving science, today announced the launch of the TaqPath Enteric Bacterial Select Panel, a CE-IVD marked panel designed to detect common gastrointestinal (GI) bacteria and help enable clinicians to identify the root cause of an infection and administer the most appropriate treatment to their patients more quickly. The panel was validated and registered under IVDD in May 2022.
Latest products offer cutting-edge research and diagnostic technologies to help advance the standard of care in infectious disease, oncology, pharmacogenomics and more